PD and subsequent treatment
| Pat . | Genetics baseline . | C15 remission . | MRD at C15 . | EOT date . | PFS date . | Time point of PD in mo, from registration date . | Period of subsequent therapy . | Name of the first subsequent therapy . |
|---|---|---|---|---|---|---|---|---|
| 1 | Del(17p) 88% TP53mut Exon 8 60% | CR | uMRD | February 2018 | September 2019 | 32.0 | ||
| 2 | Del(17p) 21.5% TP53mut Exon 8 20% | CR | uMRD | November 2017 | February 2019 | 27.2 | ||
| 3† | Del(17p) 85% TP53mut Exon 5 60% | CR | uMRD | December 2017 | September 2019 | 33.5 | From November 2018 to February 2019 | Obinutuzumab |
| 4 | Del(17p) 93.5% TP53mut Exon 8 70% | CR | uMRD | May 2018 | December 2019 | 32.1 | February 2020 | Acalabrutinib/obinutuzumab/venetoclax |
| 5 | Del(17p) 93% TP53 umut | PR | uMRD PB; no BM | November 2018 | September 2019 | 24.6 | February 2020 | Acalabrutinib/obinutuzumab/venetoclax |
| 6∗ | Del(17p) 93.5% TP53mut Exon 7 95% | PR | uMRD | December 2018 | January 2020 | 24.2 | from April 2020 to July 2020 | Venetoclax |
| 7 | Del(17p) 16.5% TP53mut Exon 6 70% | CR | uMRD PB; iMRD BM | April 2019 | June 2021 | 38.6 |
| Pat . | Genetics baseline . | C15 remission . | MRD at C15 . | EOT date . | PFS date . | Time point of PD in mo, from registration date . | Period of subsequent therapy . | Name of the first subsequent therapy . |
|---|---|---|---|---|---|---|---|---|
| 1 | Del(17p) 88% TP53mut Exon 8 60% | CR | uMRD | February 2018 | September 2019 | 32.0 | ||
| 2 | Del(17p) 21.5% TP53mut Exon 8 20% | CR | uMRD | November 2017 | February 2019 | 27.2 | ||
| 3† | Del(17p) 85% TP53mut Exon 5 60% | CR | uMRD | December 2017 | September 2019 | 33.5 | From November 2018 to February 2019 | Obinutuzumab |
| 4 | Del(17p) 93.5% TP53mut Exon 8 70% | CR | uMRD | May 2018 | December 2019 | 32.1 | February 2020 | Acalabrutinib/obinutuzumab/venetoclax |
| 5 | Del(17p) 93% TP53 umut | PR | uMRD PB; no BM | November 2018 | September 2019 | 24.6 | February 2020 | Acalabrutinib/obinutuzumab/venetoclax |
| 6∗ | Del(17p) 93.5% TP53mut Exon 7 95% | PR | uMRD | December 2018 | January 2020 | 24.2 | from April 2020 to July 2020 | Venetoclax |
| 7 | Del(17p) 16.5% TP53mut Exon 6 70% | CR | uMRD PB; iMRD BM | April 2019 | June 2021 | 38.6 |
TP53mut, TP53 mutation; umut, unmutated. Pat, patient; del, deletion; mut, mutated; umut, unmutated; C, cycle; CR, complete remission; PR, partial remission; uMRD, undectable minimal residual disease; iMRD, intermediate minimal residual disease; PB, peripheral blood; EOT, end of treatment; PFS, progression-free survival.
A Richter transformation (other: diffuse large B-cell lymphoma clonal relationship not analyzed) has been documented 12 months after EOT in May 2020, after treatment with venetoclax, rituximab/idelalisib, and ibrutinib monotherapy was administered.
Due to detectable MRD in November 2018, the patient receieved obinutuzmab. The patient had a disease progression in September 2019.